NVDA
NVIDIA
-- 140.110 RGTI
Rigetti Computing
-- 10.0400 TSLA
Tesla
-- 394.940 PLTR
Palantir
-- 68.230 AMD
Advanced Micro Devices
-- 121.840 
$Eagle Pharmaceuticals (EGRX.US)$Revenue shrank continuously...
$Eagle Pharmaceuticals (EGRX.US)$Revenue shrank continuously in the first four years over the past five years, surged by 84.6% in 2022. Operating profit fluctuated and shrank for four years, then sharply increased to 0.081 billion in 2022. Net income continued to shrink until 2021 with a loss, then increased to 0.036 billion in 2022.
Revenue fell by 43% in Q1 2023, operating profit decreased by 80.3%, and net income decreased by 87%, once again confirming the very low probability of sustainable surges, requiring very cautious handling.
The current P/E ratio is 7.8, with accumulated losses over the past four quarters, requiring observation of several more quarters before making a determination.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment